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Abstract
Recombinant and non-recombinant modified vaccinia virus Ankara (MVA) strains are currently in clinical trials as human immunodeficiency
virus-1 (HIV) and attenuated smallpox vaccines, respectively. Here we tested the ability of a recombinant MVA delivered by alternative needle-
free routes (intramuscular, intradermal, or into the palatine tonsil) to protect against immunodeficiency and orthopoxvirus diseases in a non-human
primate model. Rhesus macaques were immunized twice 1 month apart with MVA expressing 5 genes from a pathogenic simian human
immunodeficiency virus (SHIV)/89.6P and challenged intrarectally 9 months later with the pathogenic SHIV/89.6P and intravenously 2.7 years
later with monkeypox virus. Irrespective of the route of vaccine delivery, binding and neutralizing antibodies and CD8 responses to SHIV and
orthopoxvirus proteins were induced and the monkeys were successively protected against the diseases caused by the challenge viruses in
unimmunized controls as determined by viral loads and clinical signs. These non-human primate studies support the clinical testing of
recombinant MVA as an HIV vaccine and further demonstrate that MVA can provide long-term poxvirus immunity, essential for use as an
alternative smallpox vaccine.
© 2007 Elsevier Inc. All rights reserved.Keywords: SHIV/89.6P; Recombinant modified vaccinia virus Ankara; Monkeypox virus; Smallpox; Rhesus macaqueIntroduction
The development of safe and effective vaccines against
existing and emerging pathogens is a major focus of medical
research. Since the onset of the AIDS epidemic more than two
decades ago, enormous efforts have been directed to making a
vaccine that will protect against human immunodeficiency⁎ Corresponding author. Fax: +1 301 480 1535.
E-mail address: pearl@niaid.nih.gov (P.L. Earl).
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doi:10.1016/j.virol.2007.02.041virus-1 (HIV); an effective vaccine is thought to require the
induction of cellular and humoral responses (Douek et al., 2006;
Letvin, 2005; Mascola, 2003). Vaccine candidates have
included a variety of HIV immunogens delivered as DNA
(Barouch et al., 2001a; Otten et al., 2006; Rao et al., 2006),
attenuated poxviruses (Franchini et al., 2004; Ourmanov et al.,
2000; Van Rompay et al., 2005), adenoviruses (Barouch et al.,
2004; Peng et al., 2005; Shiver et al., 2002), vesicular stomatitis
virus (Egan et al., 2004), proteins (Earl et al., 2001; Xu et al.,
2006), and various combinations thereof (Hu, 2005). Our efforts
Fig. 1. Structure of MVA/KB9-5, expression of SHIV genes, and study
protocol. (A) Env and tat from SHIV/KB9 (gray boxes) and gagpol and nef
from SIVmac239 (white boxes) were inserted into deletions II and III (black
boxes) of MVA to form MVA/KB9-5. Chimeric Tatnef protein was expressed
under control of the modified P7.5 promoter; Env and Gagpol were expressed
under control of the modified H5 promoter. (B) SHIV antigens were immuno-
precipitated from cells infected with MVA/KB9-5 with: monoclonal antibody
T8 (α-env), SIV polyclonal serum E544 (α-SIV), and HIV-1BH10 Tat anti-
serum (α-tat). Precursor and cleavage products for Env and Gag are shown. The
Tatnef protein was precipitated by both Tat and Nef (E544) antibodies. (C)
Study timeline.
85P.L. Earl et al. / Virology 366 (2007) 84–97to design an HIV vaccine have focused on modified vaccinia
virus Ankara (MVA) as a vector (Moss, 1996). During repeated
passages in chick embryo fibroblasts (Mayr et al., 1975b), MVA
acquired several large deletions and small mutations including
the loss of immune defense genes restricting efficient replica-
tion to chick embryo and baby hamster kidney cells (Antoine et
al., 1998; Blanchard et al., 1998; Carroll and Moss, 1997;
Drexler et al., 1998; Meyer et al., 1991). MVA was demon-
strated to be safe in immunocompromised mice and monkeys
and tested without incident in humans (Mayr et al., 1975a;
Stickl et al., 1974; Stittelaar et al., 2001; Wyatt et al., 2004).
Because the host restriction involves a late block in morpho-
genesis, foreign genes can be expressed at high levels by the use
of an appropriate viral promoter (Carroll and Moss, 1997)
(Sutter and Moss, 1992). Furthermore, recombinant MVA
(rMVA) induces strong cellular and humoral immunity in
animal models and can be administered by numerous routes
(Sutter et al., 1994).
In the present study we evaluated an rMVA, expressing HIV
(HIV 89.6P Env and Tat) and SIV (SIVmac239 Gag, Pol and
Nef) proteins, administered by three alternative routes. Rather
than traditional needle delivery systems for intramuscular (IM)
and intradermal (ID) inoculations, we used the needle-free
Biojector, which has been reported to enhance the immuno-
genicity of a DNA vaccine in humans (Wang et al., 2001). In
addition, a study in mice demonstrating immunogenicity of a
DNA vaccine injected into the inguinal lymph nodes (Maloy et
al., 2001) prompted us to test this concept by direct delivery of
rMVA into organized lymphoid tissue of the palatine tonsils
(PT) via the Syrijet Mark II, a device used for subtopical
delivery of anesthesia in pediatric dentistry. Humoral and
cellular immune responses were determined and protection
against a SHIV/89.6P (Reimann et al., 1996) challenge was
demonstrated after only two closely spaced rMVA injections
without a DNA prime.
Recently, there has been increased interest in smallpox
vaccines because of perceived terrorists threats (Henderson,
1999). Variola virus, the causative agent of smallpox, is
closely related to vaccinia virus (VACV), which was suc-
cessfully used to eradicate smallpox (Fenner et al., 1988).
However, live VACV may be unsafe for a large segment of the
world population (Enserink, 2002; Fulginiti et al., 2003)
renewing interest in attenuated vaccine strains such as MVA,
which had never been tested for efficacy. Monkeypox virus
(MPXV), which causes a lethal human disease in parts of
Africa, is closely related to both variola and VACV and has
been used as an animal model for smallpox (Zaucha et al.,
2001) (LeDuc et al., 2002). Recent studies showed that two
immunizations with MVA protected monkeys against a lethal
challenge of MPXV (Earl et al., 2004; Stittelaar et al., 2005),
although the duration of immunity was not determined. Be-
cause the monkeys in the present study had maintained normal
CD4 counts and appeared healthy despite the SHIV infection,
we decided to challenge them with MPXV at more than 2.5
years after vaccination with rMVA in order to test the longe-
vity of poxvirus immunity. The results indicate that durable
protection against monkeypox, and by analogy smallpox, canbe achieved by MVA and would also be a collateral effect of a
recombinant MVA vaccine.
Results
Construction and characterization of MVA/KB9-5
The products of the env and gag genes are the primary
immunogens in most HIV vaccines. However, since regulatory
proteins are also targets of cytotoxic T cells (CTL), we included
a tatnef chimeric gene as well as env and gagpol genes
corresponding to those of the clonal isolate SHIV/KB9 derived
from the pathogenic SHIV/89.6P (Karlsson et al., 1997) in a
new rMVA construct called MVA/KB9-5 (Fig. 1A). Expression
of Env, Gag and Tatnef proteins was analyzed by immunopre-
cipitation. The Env precursor gp160 was produced and partially
cleaved to gp120 (Fig. 1B). In addition, the Env protein was
shown to be biologically functional in a fusion assay with cells
expressing CD4 and CCR5 or CXCR4 (not shown). Gag
precursor p55 as well as cleavage products p41 and p24 were
also made (Fig. 1B) and assembled into particles as demon-
strated by sedimentation of the medium of infected cells through
a 20% sucrose cushion (not shown). Tatnef was immunopre-
cipitated by both anti-tat antibody and serum from a SIV-
infected monkey and migrated at the predicted mass of 40.5 kDa
(Fig. 1B). Localization of Tatnef in the cytoplasm of infected
cells was demonstrated by immunofluorescence (not shown).
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The study timeline is shown in Fig. 1C. Thirty rhesus
macaques were immunized with 2×108 infectious units of
either MVA/KB9-5 or non-recombinant MVA at weeks 0 and 4
using needle-free methods of administration. The Biojector was
used for IM and ID immunizations and the Syrijet Mark II for
delivery into the PT. To minimize variability, all MVA doses
were delivered into two sites on each animal, i.e., into both legs
or both PTs. Eight monkeys were placed in each of the ID and
IM groups; seven were placed in each of the PT and control
groups. Control animals were subdivided such that three
received non-recombinant MVA via the IM or ID route and
two received it in the PT. Macaques used in the study were pre-
screened and 15 MamuA⁎01+ animals were selected to allow
analysis of CD8+ T cell responses to the immunodominant gag
epitope CM9. Four MamuA⁎01+ animals were assigned to each
of the MVA/KB9-5 groups and three to the control MVA group.
The SHIV challenge was intrarectal, as the mucosal route
mimics the predominant method of human HIV transmission,
and was performed 9 months after immunization to allow
immune responses to recede into memory.Fig. 2. Temporal immune responses induced by vaccination with MVA/KB9-5 and ch
ELISA with KB9 gp140 captured via antibody to the C-terminus of gp120. Average
89.6P neutralizing antibody titers were determined in an MT-2 cell-killing assay. Tite
group are shown with standard errors. (C) The percent of CD8 Tcells that were positiv
animals; averages for each group are shown. (D) Frequencies of Gag-, Env-, Tat-
stimulated for 36 h with pools of approximately 10 peptides. Averages for each grou
naive (unimmunized) black bars. Arrowheads indicate times of MVA immunizationAt 2.7 years after SHIV challenge, all but one of the
vaccinated animals was alive: plasma SHIV RNA was
undetectable and CD4 cell counts were in the normal range.
At this time, we assessed the ability of the memory immune
responses in these SHIV-infected monkeys to protect against
MPXV. Thus, six monkeys (two from each immunization
group) were challenged intravenously with a potentially lethal
dose of MPXV. To determine the ability of rMVA to boost
immune responses in SHIV-infected animals, the 16 remaining
monkeys were re-immunized with MVA/KB9-5 more than 3
years after the initial immunizations.
Vaccine-induced SHIV antibody responses
Env-binding and SHIV/89.6P neutralizing antibody titers
were measured after MVA/KB9-5 immunization. All animals
developed similar levels of KB9 gp140-binding antibodies (Fig.
2A), with those immunized in the PT having significantly
higher values than others only at week 6 (pb0.006 for
comparisons with IM and ID). In a previous study (Earl et al.,
2002) employing IM needle delivery of an rMVA that expresses
the 89.6 env, the binding antibody titers were significantlyallenge with SHIV/89.6P. (A) Serum antibody endpoint titers were measured by
titers for each immunization group are shown with standard errors. (B) SHIV/
rs are the reciprocal of the dilution giving 50% neutralization; averages for each
e for the gag CM9 peptide was measured by tetramer binding in the MamuA⁎01+
and Nef-specific cells were measured by IFN-γ ELISpots. Fresh PBMC were
p are shown as follows: PT, white bars; ID, light gray bars; IM, dark gray bars;
; stars indicate day of challenge with SHIV/89.6P.
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average reciprocal titer of 4500 (pb0.025 for comparison of
two IM delivery modes). Neutralizing antibody to SHIV/89.6P
was elicited in 2, 4, and 3 of the animals in the PT, ID, and IM
groups, respectively, with reciprocal titers ranging from 29 to
262 (Fig. 2B). In addition, several of these animals also had low
neutralizing activity against the partially heterologous SHIV/
89.6, with reciprocal titers ranging from 32 to 71. In contrast, no
neutralizing activity was previously found after two IM
immunizations using needle delivery (Earl et al., 2002).
Because the two delivery systems were not evaluated
concurrently, further evaluation of the Biojector for IM delivery
of MVA is warranted.
Vaccine-induced SHIV T cell responses
T cell responses to the immunodominant Gag epitope CM9
were measured by tetramer staining in the MamuA⁎01+ animals
(Altman et al., 1996) (Fig. 2C). All MVA/KB9-5-immunized
animals had detectable responses after a single immunization
(0.31 to 1.34% tetramer+/CD8+ cells), which were boosted in
most animals after the second immunization (0.29 to 2.87%
tetramer+/CD8+ cells). The responses appeared sooner in the PT
group than in the others with averages at 1 week after
immunization of 0.53, 0.17 and 0.18% tetramer+/CD8+ cells
in the PT, ID, and IM groups, respectively. However, by the
second week and at every time point thereafter, differences
between groups were not observed.
T cell responses to the entire Gag, Env and Tatnef proteins
were measured in an ELISpot assay using pools of overlapping
peptides (Fig. 2D). Gag and Env-specific T cells were generated
by a single MVA/KB9-5 immunization and were somewhat
lower on average after the second immunization. Gag responses
ranged from none to 468 and none to 595 spots per million cells
(weeks 1 and 5, respectively) although every animal had a
measurable response at a minimum of one time point. At week
5, Gag responses were significantly higher in the PT as
compared to the IM group (p=0.034). Env responses were
found in every animal at both time points with values ranging
from 273 to 2293 and 45 to 1553 spots per million cells at weeks
1 and 5, respectively. Although values were higher in the PT
group the differences were not statistically significant. ELISpot
responses to the immunodominant Gag epitope CM9 were also
measured (not shown). These followed the same pattern found
with CM9 tetramer staining, i.e., they were higher after the
second immunization than after the first. The frequencies of Tat-
and Nef-specific T cells were low with only half of the animals
having any response at either time point.
SHIV/89.6P challenge
Nine months after the second rMVA immunization, the
animals were challenged intrarectally with 20 infectious units of
SHIV/89.6P (1.2×1010 copies of SHIV/89.6P RNA) as
described (Amara et al., 2001). All of the control and all but
one of the vaccinated animals (Rh641 in the IM group) became
infected as judged by increased humoral and cellular responsesto Env and Gag (Fig. 2). Control animals exhibited a rapid and
profound loss of CD4 T cells within 3 weeks after challenge
(Fig 3) and died between 8 and 13 months. In contrast, all but
one of the vaccinated animals remained healthy for more than 2
additional years. An outlier Rh606 in the PT group became ill
and died at month 17 after challenge. CD4 T cell counts were
significantly lower in controls than in vaccinated groups
between weeks 3 and 20 (pb0.0019).
At peak viremia, 2 weeks after challenge, the geometric
mean RNA viral load was greater than one log lower in the
immunized groups than in the control group (p=0.0339,
0.0017, and 0.0175 for PT, IM, ID, respectively) (Fig. 4). By
8 weeks, the geometric mean titers in the immunized groups
were greater than two logs lower than in the control group
(pb0.006) but there were no significant differences between
any of the vaccine groups.
SHIV/89.6P-induced immune responses
Rapid and strong anamnestic Env-binding and SHIV
neutralizing responses occurred in the vaccinated animals
after challenge (Figs. 2A, B). The average reciprocal Env
ELISA titer for each vaccine group was greater than 165,000
and 970,000 at weeks 2 and 3, respectively, and was 1,368,000
at week 196. This long-lasting response was likely due to
persistent low-level SHIV/89.6P infection. SHIV/89.6P neu-
tralizing antibody titers also rose dramatically after challenge
with average reciprocal titers greater than 1700 and 6500 at
weeks 2 and 3, respectively. In contrast, neither Env-binding nor
SHIV neutralizing antibodies were detected in any of the control
animals until week 8.
T cell responses were also boosted rapidly in vaccinated
animals after SHIV challenge (Figs. 2C, D). Tetramer binding
increased from an average of 0.15% to 3.6% tetramer+/CD8+
cells by 2 weeks after challenge in vaccinated animals. Average
Gag and Env ELISpots increased from 31 to 799 and from 118
to 1004 spots per million cells, respectively, by 2 weeks after
challenge.
At 3.7 years after vaccination, sixteen of the animals were
boosted with MVA/KB9-5 by the same route as their initial
immunizations. There was no increase in HIV Env-binding
titers, likely reflecting the persistence of antibody at high levels
as noted above. However, there was a 2-fold (p=0.309) increase
in tetramer and 3.3-fold (p=0.0025) increase in Gag ELISpot
values after boosting (not shown).
VACV immune responses
Immune responses to both VACV MV and EV were
determined in several assays shown in Fig. 5. For the VACV-
binding and neutralizing analyses, the pre-challenge data from
animals immunized with MVA and MVA/KB9-5 were com-
bined, as they were similar. Titers for binding and neutralizing
antibodies to VACV (Figs. 5A, D) were higher in the ID and IM
groups than they were in the PT group (pb0.041 for binding
and ≤0.0031 for neutralizing antibodies) at week 6 and
thereafter. Antibody titers to the MV protein L1 (Fig. 5B) and
Fig. 3. CD4 T cell counts after challenge with SHIV/89.6P. CD4 cell counts of individual animals are shown in the four lower panels with animal deaths indicated by a
cross (all naive, one P.T.-immunized animal). The geometric mean for all groups is shown in the top panel.
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groups than in the PT group. Antibodies to the EV form of
VACV were determined by two methods: a plaque reduction
assay that directly measures neutralization of EV (Fig. 5E) and a
comet reduction assay that measures inhibition of satellite
plaque formation (Fig. 5F). Strong EV neutralizing activity,
comparable to that of VACV immune globulin, was found in all
animals at week 6. Although this activity declined by week 134,
it was still readily demonstrable in all animals. Similarly, comet
reduction was highest at 6 weeks.
To examine the boosting effect of rMVA after a prolonged
period of time, the remaining sixteen animals were re-
immunized 3.7 years after the initial immunization. VACV
MV-binding and neutralizing titers which had slowly declined
as shown in Fig. 5 were enhanced by this third immunization to
levels equivalent to that elicited immediately after the second
immunization (not shown).
VACV-specific interferon (IFN)-γ producing CD8 cells were
enumerated using cryopreserved cells obtained 1 week after the
first (week 1) and second (week 5) rMVA immunization as well
as from a later time point (week 34) when responses had
receded into memory. Positive responses were detected in 6/15,
13/20, and 18/20 animals at weeks 1, 5, and 34, respectively
(Fig. 6). No differences were seen between the three routes ofimmunization. Although higher responses would be expected
immediately after immunization, we found the highest percent
of IFN-γ producing cells at the later time point. This may be
explained by the observation (R.R.A., unpublished) that cells in
memory are more efficiently revived after freezing.
MPXV challenge
Two and a half years after the second MVA/KB9-5
immunization, six of the monkeys (two from each immuniza-
tion group) were challenged intravenously with 5×107
infectious units of MPXV to determine the long-term protective
effect of immunization with rMVA. At this time the VACVMV-
binding antibody titers had declined to less than 1:6400 and
neutralizing titers to less than 1:563. Two naive rhesus monkeys
were added to the study as negative controls. MPXV load and
appearance of lesions were monitored every 3 days and are
shown in Figs. 7A and B, respectively. The peak viral load was
lower by 2.5 logs in the immunized as compared to the naive
animals. The difference between the two groups was statisti-
cally significant from days 3 through day 12 (pb0.0054). Also,
the naive monkeys developed large numbers of lesions and
became seriously ill. As is typical in rhesus macaques, the
lesions resolved by day 22 after infection. In contrast, the
Fig. 4. SHIV viral load. The number of copies of SHIV RNA per milliliter of plasma was determined by quantitative PCR (Cline et al., 2005). Data from individual
animals are shown in the four lower panels; geometric means for all groups are shown in the top panel.
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small and atypical in appearance and resolved quickly. Most
importantly, the vaccinated animals showed no clinical signs of
illness. In the vaccinated animals, no correlations were found
between the magnitude of the pre-challenge immune responses
and the post-challenge viral load or numbers of lesions.
Discussion
The major conclusions of this study are that only two
vaccinations with an rMVA administered by any of three routes
provide durable protection against disease caused by a patho-
genic SHIV as well as long-term immunity to a severe MPXV
challenge. Previous studies showed that repeated immunizations
with rMVAs expressing HIVand/or SIV proteins, either alone or
as a boost to a DNA vaccine, induce immune responses that
partially protect against SHIV or SIV challenge (Amara et al.,
2001, 2002b; Barouch et al., 2001b; Earl et al., 2002; Ourmanov
et al., 2000; Van Rompay et al., 2005). In anticipation of Phase I
clinical trials utilizing rMVA viruses developed in our
laboratory, we evaluated a simplified vaccine strategy consisting
of only two immunizations given within a 1-month period. In
addition, we compared various routes of immunization.
Although the SHIV/89.6P model does not precisely mimic the
course of HIV in humans, it does allow the use of HIV env and
other genes in a pathogenic non-human primate model. Thus our
rMVA contained HIV-1 env and tat genes in addition to SIVgag, pol and nef genes. Strong early/late VACV promoters were
used to drive high level expression of native Env, Gag and Pol
and a chimeric fused form of Tat and Nef.
We determined that two immunizations with rMVA, given 1
month apart, were sufficient to protect monkeys against disease
induced by a lethal dose of SHIV/89.6P, and that similar
protection was achieved irrespective of the IM, ID, or PT route
of immunization. In contrast, control animals rapidly lost CD4
T cells, succumbed to disease characterized by low CD4 count
and were euthanized within 8–13 weeks after challenge. The
peak and setpoint RNA loads in the vaccinated animals were
significantly lower than that in naive controls. Additionally, the
protected animals maintained normal CD4 T cell levels, good
health, and undetectable viral RNA for up to 3.5 years after
challenge. A similar level of protection against intrarectal
challenge with SHIV/89.6P was reported in several papers by
Amara et al. (2001, 2002b). In those reports, animals received
either an rDNA prime/rMVA boost or three rMVA immuniza-
tions. Interestingly, although the rDNA/rMVA protocol induced
much higher levels of Gag-specific T cells than did the rMVA
protocol, the protection was indistinguishable. Also, the third
rMVA immunization resulted in only a minor increase in Gag-
specific T cells. Here we showed that Gag- as well as Env-
specific T cell responses were higher after one than after two
rMVA immunizations. Nevertheless, antibody titers as well as
CM9 tetramer responses were boosted after the second
immunization. It would be interesting to challenge monkeys
Fig. 5. Temporal VACV antibody responses. (A, B, C) Serum antibody titers were determined by ELISA against purified VACV MV particles, purified VACV L1
protein, and purified VACV B5 protein. Average titers with standard errors are shown for animals immunized by each route: PT, diamond; ID, square, IM, triangle.
Times of MVA immunization are shown with arrowheads; star indicates day of challenge with SHIV/89.6P. (D) Neutralizing antibody titers were determined using a
flow cytometric assay that measures reduction in infectivity of a VACVexpressing EGFP (Earl et al., 2003). Symbols as above. (E) Percent neutralization of VACV EV
was determined in the presence of excess L1Mab 7D11. Serum samples from individual animals were assayed and the averages for animals in each group are indicated
as: PT, light gray; IM, medium gray; ID, black. Vaccinia virus immune globulin (VIG) was used as a positive control. (F) A comet reduction assay was performed using
VACV strain IHD-J. Serum samples from all animals were assayed and one representative example from each immunization group is shown.
Fig. 6. INF-γ producing MVA-specific CD8 cells. Quantitation of VACV-
specific IFN- γ producing cells was performed on cryopreserved PBMC after
infection with MVA overnight. Each dot represents one animal with positive
values (N2-fold background) located above the shaded area. The average for
each time point is denoted by a line.
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protective immunity at that time.
Although the route of immunization did not affect the degree
of protection against SHIV/89.6P, we did observe small
differences in immune responses. Gag and Env ELISpot and
Env-binding antibody titers were higher in the PT-immunized
group, but the differences were not always significant. Two
individual animals were outliers in the study: animal Rh606 in
the PT group who succumbed to disease and animal Rh641 in
the IM group who resisted infection. However, in comparison to
the other animals in the study, neither of the outliers had
noticeably different immune responses that could account for
their fates. Although a correlation between Gag-specific T cell
responses and levels of SHIV RNA in individual animals after
challenge has been reported (Barouch et al., 2001b), no direct
correlation between the magnitude of any of the immune
responses measured and the level of SHIV RNA were found
here.
Fig. 7. MPXV challenge. (A) Following challenge with MPXV, the number of MPXV genomes per milliliter of blood was determined by quantitative TaqMan PCR.
Average values for MVA-immunized and naive groups are shown. (B) The number of lesions induced by MPXV challenge was enumerated every 3 days for 2 weeks
after challenge. The number of lesions found on each animal is shown.
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cause it was reported to generate higher immune responses
(Wang et al., 2001), while avoiding the use of needles. Although
we did not perform a direct comparison, we have previous
experience using a needle for IM delivery of a related rMVA
(Earl et al., 2002). In comparing the results of the two studies,
there was significantly higher Env-binding antibody to the
respective matched gp140 proteins and some neutralizing
antibody responses to SHIVs after only two immunizations
with the Biojector, possibly due to wider distribution of the virus
at the site of inoculation. However, a direct comparison of the
two inoculation methods is needed to confirm this impression.
Our previous non-human primate studies utilized an rMVA
that contained only env and gagpol immunodeficiency virus
genes (Earl et al., 2002; Amara et al., 2002a). To potentially
increase immunity to the challenge virus and to examine
immune responses to accessory proteins, we included tat and
nef sequences in the new rMVA. Both Tat and Nef are
expressed early after infection with HIV and induce CTL
(Addo et al., 2001; Sriwanthana et al., 2001). In addition,
immune responses to vaccines containing tat and nef have
been obtained (Cafaro et al., 2001; Hel et al., 2002; Richardson
et al., 2002) and there is a report that immunization with tat
alone can be protective (Cafaro et al., 2001). However, in the
present study only a few animals developed ELISpot responses
to Tat and Nef and these were low and sporadic. The fact that
responses were high after challenge indicates that the earlier
low results were not artifactual false negative results due to the
assay. Although we demonstrated good expression of thechimeric protein in tissue culture experiments, evidently it was
not very immunogenic.
Development of a smallpox vaccine with an improved safety
profile over the licensed Dryvax vaccine is currently a priority
(Fulginiti et al., 2003). Because MVA was shown to be safe in
immune compromised non-human primates (Stittelaar et al.,
2001) and was tested without apparent adverse effects in over
120,000 people (Mayr et al., 1975a; Stickl et al., 1974), it is
being considered as an alternative smallpox vaccine. However,
since smallpox has been eradicated, the efficacy of MVA cannot
be tested in humans. Instead, protection must be demonstrated in
suitable animal models. Toward this end, we and others showed
that two immunizations of non-recombinant MVA strongly
protected cynomolgous monkeys against a lethal dose of MPXV
administered shortly after vaccination (Earl et al., 2004;
Stittelaar et al., 2005). Here we evaluated the long-term
immunity induced by a similar vaccination protocol in rhesus
macaques. While the VACVantibodies declined in the monkeys
during the 2.7-year period between vaccination and challenge,
sufficient memory remained to provide solid protection against
the MPXV challenge. Additionally, these animals resisted
MPXV challenge in the face of SHIV infection that had been
controlled for more than 2 years. That these monkeys had normal
CD4 T cell counts was likely crucial, as in another study, SHIV-
infected monkeys with low CD4 T cell counts succumbed
readily toMPXV challenge (Edghill-Smith et al., 2005). (Nigam
et al. 2007) have also found long-lived protective immunity to
MPXV in rhesus macaques that were vaccinated twice with
another rMVA but not challenged with SHIV.
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at 3.7 years after their initial immunization to determine the
efficiency of boosting after a prolonged period of rest. The
HIV Env antibody titers were high at the time of re-
immunization, probably due to persistent low-level infection
with SHIV/89.6P, and no increase in titer was observed.
Nevertheless, there was more than a 2-fold increase in Gag
ELISpot and tetramer values after boosting. In contrast, VACV
does not cause a persistent infection and the VACV MV
ELISA and neutralizing titers increased by more than one log
within 1 week of boosting, showing that a rapid anamnestic
response could be elicited.
In conclusion, we described a simplified vaccination
schedule in which an rMVA protected against disease following
challenge with a pathogenic SHIV 9 months later and a MPXV
challenge 2.7 years later. These results indicate that immunity to
orthopoxviruses may be a collateral benefit of an MVA HIV
vaccine.
Materials and methods
Cells and viruses
BSC-1 cells (ATCC CCL-26) and RK13 cells (ATCC CCL-
37) were maintained at 37 °C in modified Eagle's minimal
essential medium (EMEM) supplemented with 10% heat-
inactivated fetal bovine serum (FBS, Hyclone, Logan, UT),
2 mM L-glutamine (Invitrogen, Carlsbad, CA), 100 U/ml
penicillin and 100 μg/ml streptomycin (Invitrogen). HeLa S3
cells (ATCC-CCL-2.2) were maintained in suspension in MEM
for spinner cells (Quality Biologicals, Inc., Gaithersburg, MD)
containing 5% heat-inactivated equine serum (Hyclone).
VACV strain Western Reserve (WR) (ATCC VR-1354), VV-
NP-S-EGFP (Anton et al., 1999; Norbury et al., 2002) and IHD-J
(S. Dales, Rockefeller University, NY), were grown in HeLa S3
cells and purified by sucrose density centrifugation. MPXV
strain Zaire 79 (V-79-I-005) isolated from the scab of an infected
human by incubation in LLC-MK2 cells and then passaged
twice in BSC-40 cells was obtained from J. Esposito (Centers for
Disease Control, Atlanta) and propagated in MA-104 cells. A
titered clarified lysate was used for the MPXV challenge.
Construction of MVA/KB9-5
Recombinant virus, MVA/KB9-5, expressing 5 genes
corresponding to those in SHIV/89.6P was constructed. An
MVA shuttle plasmid containing env, and a chimeric tatnef was
constructed in 3 steps. Step 1: The env gene, originating from
pSHIV/KB9 3′end (J. Sodroski, AIDS Repository) (Karlsson et
al., 1997) was cloned into pLW17 and two modifications were
made. First, the cytoplasmic tail was truncated by 393
nucleotides, generating the amino acid sequence EEGERD at
the C-terminus. Second, a silent mutation was made at
nucleotide 1149 (T to C) (Quik Change kit, Stratagene) to
eliminate a naturally occurring VACV early transcription
termination signal (Earl et al., 1990). The resulting plasmid
was called pLW-KB9env. Step 2: A chimeric tatnef gene wasconstructed as follows: the tat gene was generated by ligation of
12 overlapping synthetic oligonucleotides followed by PCR
amplification. The sequence used was from pSHIV/KB9 3′end
with the following changes: the nuclear localization signal,
RKKRR, was not included and codons overlapping with the
env gene were changed to prevent potential recombination
between env and tat genes in the recombinant MVA. The
SIVmac239 nef gene was amplified from pSHIV KB9 3′end
such that the newly generated 5′end overlapped with the 3′end
of the tat gene. The tat and nef DNA products were mixed and
amplified using oligonucleotides designed to generate a
chimeric tatnef gene with BamHI and KpnI at the 5′ and 3′
ends, respectively. Step 3: a DNA fragment containing the
modified p7.5 promoter was amplified from pLW40 (L.S.W.
and B.M., unpublished) to generate a fragment containing KpnI
and BamHI at the 5′ and 3′ends, respectively. Finally, tatnef
and promoter fragments were ligated simultaneously into
pLW17-KB9env that had been linearized with KpnI (5′end)
and BamHI (3′end) to generate pLW-KB9env/tatnef. pLW17-
KB9env/tatnef was inserted into deletion II of vJH4, a virus that
contains the SIVmac239 gagpol gene in deletion III, by
homologous recombination using standard techniques.
Sequences of the chimeric tatnef gene and of oligonucleotides
used in cloning will be provided upon request.
Immunoprecipitation of viral antigens
Infection, metabolic labeling, and immunoprecipitation were
performed as previously described (Sugiura et al., 1999).
Briefly, BSC-1 cells were infected with 5 pfu/cell of rMVA.
Five hours post-infection, cells were washed and overlaid with
methionine-free EMEM containing 5% dialyzed FBS and
100 μCi of [35S]methionine (New England Nuclear, Boston,
MA) per milliliter. After 20 h, cells were lysed in buffer
containing 100 mM Tris–HCl, pH 8.0, 100 mMNaCl, and 0.5%
Triton X-100. Lysates were clarified by centrifugation for 10
min at top speed in a microcentrifuge and subjected to
immunoprecipitation. Antibodies used were: T8 monoclonal
antibody to gp120 (P.L.E. and B.M., unpublished), serum E544
from a SIV-infected monkey (gift of V. Hirsch) or HIV-1 BH10
Tat antiserum (AIDS Repository, cat #705). Immunoprecipi-
tated proteins were separated by 10% polyacrylamide SDS
electrophoresis and visualized by autoradiography.
Immunization and challenge of rhesus macaques
The study utilized a total of 30 monkeys (Macaca mulatta)
from Morgan Island, SC, fifteen of which were MamuA⁎01, as
determined by the Wisconsin Regional Primate Research Center
MHC Typing Core. Immunization and SHIV challenge were
conducted at Bioqual, Inc., Rockville, MD, an AAALAC-
International accredited facility, in accordance with NIAID
animal care and use protocols. Three needle-free routes of
immunization were employed for MVA administration. Each
dose was administered at two sites for a total amount of 2×108
infectious units. A Syrijet Mark II apparatus (Mizzy, Inc., Cherry
Hill, NJ) was used for immunization directly into the PT in a
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performed using a Biojector (Bioject Medical Technologies,
Inc., Portland, OR), delivering 0.5 ml and 0.1 ml per site,
respectively. Control animals received non-recombinant MVA
via the same routes (3 animals ID, 2 animals IM, 2 animals in
PT). Immunizations were performed at weeks 0 and 4 in all
animals. The IM and ID groups contained 8 animals each; the PT
and control groups contained 7 animals each. Vaccine and
control groups were assigned four or three MamuA⁎01 animals,
respectively. All monkeys were challenged with 20 intrarectal
infectious units of the pathogenic SHIV/89.6P by the intrarectal
route at week 41.
KB9 env ELISA
Immulon-2-HB 96-well microtiter plates (Thermo Labsys-
tems, Franklin, MA) were coated overnight at 4 °C with sheep
antibody to the C-terminus of gp120 (Cliniqa Corporation,
Fallbrook, CA) at 2.2 μg/ml in CB1 bicarbonate buffer
(Immunochemistry Technologies, Bloomington, MN).
KB9gp140, purified from the medium of BSC-1 cells infected
with MVA/KB9gp140 (P.L.E. and B.M., unpublished), was
diluted in blocking buffer (PBS containing 5% non-fat dry milk
and 0.2%Tween 20) to a concentration of 0.6 μg/ml and captured
for 2 h at room temperature. Plates were incubated with blocking
buffer for 1 h at room temperature. Two-fold serial dilutions of
monkey sera were incubated for 2 h at room temperature
followed by horseradish peroxidase-conjugated anti-monkey IgG
(Accurate Chemical and Scientific Corp, Westbury, NY) for 1 h
at 37 °C and then 3,3′,5,5′-tetramethylbenzidine (BM Blue, POD
substrate Roche Molecular Biochemicals) for 30 min at room
temperature. Absorbency was measured at 370 and 492 nm.
Neutralization of SHIV/89.6P
Neutralization was measured in an MT-2 cell assay as
described previously (Crawford et al., 1999). Virus stocks were
produced in human peripheral blood mononuclear cells
(PBMC). Titers of neutralizing antibodies are presented as the
reciprocal of the serum dilution that reduced virus-induced cell
killing by 50% as measured by neutral red dye uptake.
Tetramer staining
Approximately 106 fresh PBMC were surface stained with
PE-conjugated CM9-MamuA⁎01 tetramer (AIDS Tetramer
Facility) (Altman et al., 1996) for 30 min at 4 °C followed by
anti-CD3 FITC (Becton Dickinson, San Jose, CA) and anti-CD8
APC (Becton Dickinson) for 30 min at 4 °C. After washing with
PBS, cells were fixed with 2% paraformaldehyde and analyzed
with a FACSCalibur (Becton Dickinson) using Cell Quest and
FlowJo software (Treestar, Inc., Ashland, OR).
IFN-γ ELISpot
96-Well Multiscreen IP plates (Millipore Inc., Bedford, MA)
were briefly soaked with 100 μl of 70% ethanol and then rinsed3× with deionized water. Plates were coated with 50 μl of GZ-4
anti-human IFN-γ (Mabtech, Mariemont, OH) at 5 μg/ml in 1×
Dulbecco's phosphate-buffered saline (DPBS) without Ca+ or
Mg+ for 2 h at 37 °C. Plates were washed 3× with DPBS and
blocked with 150 μl Roswell Park Memorial Institute (RPMI)
buffer containing 10% FBS for at least 30 min at 37 °C. After
incubation, RPMI was removed and 50 μl peptide pools at a
concentration of 4 μg/ml were added to each well. Plates were
then seeded with 2×105 fresh PBMC/well. Final concentration
of peptide was 0.2 μg in 100 μl. Peptides used were as follows:
fifty SIVmac239 Gag peptides (20-mers overlapping by 10
amino acids, AIDS Repository, cat #4495-4544) were dissolved
at 1 mg/ml in either water or dimethylsulfoxide according to the
Repository recommendations. Five pools containing 10 pep-
tides each were prepared and stored in aliquots. Twenty-one
pools, each containing 10 peptides, spanning the entire 89.6 Env
coding sequence (15-mers overlapping by 11 amino acids).
Peptides in pool #21 were from the C-terminus of gp160, a
region not included in the protein expressed in MVA/KB9-5,
and served as a background control. Peptides spanning the
Tatnef chimeric protein (15-mers overlapping by 11) were
synthesized by Emory University Microchemical Facility,
Winship Cancer Center. These were dissolved in dimethylsulf-
oxide at a concentration of 100 mg/ml and subsequently diluted
and pooled (10 per pool) for use in the assay. Cells were
stimulated with peptides for approximately 36 h in a CO2
incubator at 37 °C. The plates were washed six times with
DPBS containing 0.05% Tween 20. Biotinylated 7B6-1 anti-
human IFN-γ antibody (Mabtech 7B6-1) at 2 μg/ml was added
for 2 h at 37 °C followed by washing and incubation with avidin
peroxidase (Vectastatin ABC Elite Kit, Vector Laboratories,
Burlingame, CA) according to the manufacturer's directions.
Spots were developed with peroxidase substrate (Vectastatin
AEC Substrate) and enumerated with an automated ELISpot
reader (ZellNet Consulting, Inc., Fort Lee, NJ). The number of
background spots ranged from 0 to 95/106 but was typically
under 15/106 cells. Only counts of greater than 20/106 cells after
subtraction of background were used.
CD4+ T cell counts
CD4+ T cells were enumerated by flow cytometry at
Advanced Biosciences Laboratories, Inc. (Kensington, MD).
Plasma SHIV RNA copy number
SHIV RNA copy number was enumerated by quantitative PCR
using plasma collected after SHIV infection (Cline et al., 2005).
VACV MV ELISA
VACV strain WR mature virions were purified by sucrose
gradient sedimentation from lysates of infected HeLa cells and
used to coat 96-well microtiter plates (Thermo Labsystems) at
107pfu/ml in CB1 bicarbonate buffer (Immunochemistry
Technologies) at 37 °C overnight. Liquid was removed from
the plates and virus was inactivated by incubation with 2%
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buffer (0.15M NaCl, 0.5% Tween 20), blocked for 1 h with
blocking buffer (PBS containing 5% non-fat dry milk and 0.2%
Tween 20) and subsequently incubated with 2-fold dilutions of
sera for 1 h at 37 °C. Peroxidase conjugated anti-monkey IgG
(Accurate Chemical and Scientific Corp.) was added at a
dilution of 1:4000 and incubated for 1 h at 37 °C followed by
BM Blue substrate (Roche Molecular Biochemicals) for 30 min
at room temperature. Absorbency was measured at 370 and
492 nm.
VACV L1 and B5 protein ELISA
96-Well microtiter plates were coated overnight at 4 °C with
either soluble recombinant L1 (0.4 μg/ml) or B5 (1 μg/ml)
protein diluted in PBS. Both proteins were produced in insect
cells infected by a recombinant baculovirus and purified from
the medium by nickel affinity (Aldaz-Carroll et al., 2005a,
2005b). Plates were washed, blocked, and endpoint titers for
individual serum samples determined as described above for
MV ELISA.
VACV mature virus neutralization assay
Neutralization of VACV WR was performed as previously
described using a flow cytometric assay employing a recombi-
nant virus expressing EGFP (Earl et al., 2003).
Comet reduction assay
BSC-1 cells were infected with the VACV strain IHD-J,
which produces comet-like satellite plaques due to the release
of large amounts of extracellular virus. After 2 h, monolayers
were washed three times and overlaid with medium contain-
ing serum samples diluted 1:66. After 40–44 h, cells were
stained with crystal violet and photographed.
VACV EV neutralization assay
For production of extracellular virus (EV), RK-13 cells
were infected with VACV strain IHD-J at a multiplicity of
infection of 0.1 plaque forming units for 1.5 h after which the
monolayer was washed twice and overlaid with EMEM
containing 2.5% FBS. Approximately 20 h after infection, the
EV-containing medium was transferred to a conical tube and
debris was removed by low speed centrifugation. Serum
samples (1:5 final dilution) were incubated with 10 μl of EV
in PBS containing 3% bovine serum albumin and 6.9 μg/ml
VACV L1 monoclonal antibody 7D11 in 96-well round
bottom plates. The amount of 7D11 used was determined to
be more than sufficient to neutralize the contaminating MV
virus in the EV preparation. After 1.5 h at 37 °C, samples
were diluted and used to infect monolayers of BSC-1 cells in
6-well plates. The volume used for infection was determined
empirically to give 90–150 plaques/well. Samples were plated
in quadruplicate. After 48 h, cells were stained with crystal
violet and plaques were enumerated. The percent neutraliza-tion was determined by the formula: 100−number of plaques
with test sample and 7D11 MAb×100 /number of plaques
with 7D11 MAb only. VACV Immune Globulin (Cangene
Corp., Winnipeg, Canada) was included as a positive control
in all experiments.
VACV-specific IFN-γ producing PBMC
Quantitation of VACV-specific IFN-γ producing cells was
performed on cryopreserved cells as follows. Cells were thawed
at 37 °C and transferred to a 50-ml conical tube. Ten milliliters
of warm RPMI containing 10% FBS (RPMI-10) and 50 U/ml
benzonase nuclease (Novagen, CN Biosciences, Inc., Madison,
Wisconsin) were slowly added to the tube. Cells were
centrifuged for 5 min at 1200 rpm, washed once in RPMI-10
containing benzonase, and suspended in 1 ml of RPMI-10.
After overnight incubation at 37 °C, they were centrifuged at
1200 rpm for 5 min and suspended in RPMI-10 containing
CD28 and CD49d (BD Biosciences, San Jose, CA) each at a
final concentration of 1 μg/ml. Cells were either infected with
MVA at a multiplicity of infection of 6, stimulated with PMA
(50 ng/ml)/ionomycin (2 μg/ml) or unstimulated. After 7 h,
brefeldin Awas added to a final concentration of 10 μg/ml and
incubation was continued overnight. Cells were then washed
with 3 ml RPMI-10, stained for 30 min at 4 °C with CD8
fluorescein isothiocyanate and CD3 phycoerythrin (BD Bios-
ciences), treated with Cytofix/cytoperm (BD Biosciences), and
stained for 30 min at 4 °C with IFN-γ allophycocyanin (BD
Biosciences). After washing, cells were suspended in 2%
paraformaldehyde and acquired on a FACSCaliber using
CellQuest software. Analysis was performed using FlowJo
software (TreeStar, Inc., Ashland, OR).
MPXV challenge
Immunized and control monkeys were delivered to USAM-
RIID, Ft. Detrick, MD, where they were challenged with 5×107
infectious units of MPXV by the intravenous route. The number
of monkeypox genomes per milliliter of blood was determined
by extraction of DNAwith the QIAGEN QIAmp DNA mini Kit
and quantitative TaqMan-MGB PCR as previously described
(Earl et al., 2004). Monkeypox lesions were enumerated every 3
days after challenge.
Statistical analysis
Statistical differences between vaccine groups were assessed
by ANOVA using Statview software (SAS Institute Inc., Cary,
NC).
Acknowledgments
We thank Norman Cooper for the cells and VACV. Vanessa
Hirsch kindly provided E544 monkey serum and Gary Cohen
and Roselyn Eisenberg provided VACV recombinant pro-
teins. Additional materials were obtained from the NIAID
AIDS Repository, the NIAID AIDS Tetramer Facility, and
95P.L. Earl et al. / Virology 366 (2007) 84–97BEI Resources. MamuA⁎01 typing was performed by the
Wisconsin Regional Primate Research Center MHC Typing
Core. Richard Stout provided assistance with the Biojector. This
work was supported in part by funds from the intramural
program of NIAID, NIH.
References
Addo, M.M., Altfeld, M., Rosenberg, E.S., Eldridge, R.L., Philips, M.N.,
Habeeb, K., Khatri, A., Brander, C., Robbins, G.K., Mazzara, G.P., Goulder,
P.J., Walker, B.D., 2001. The HIV-1 regulatory proteins Tat and Rev are
frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected
individuals. Proc. Natl. Acad Sci. U.S.A. 98, 1781–1786.
Aldaz-Carroll, L., Whitbeck, J.C., Ponce de Leon, M., Lou, H., Hirao, L., Isaacs,
S.N., Moss, B., Eisenberg, R.J., Cohen, G.H., 2005a. Epitope-mapping
studies define two major neutralization sites on the vaccinia virus
extracellular enveloped virus glycoprotein B5R. J. Virol. 79, 6260–6271.
Aldaz-Carroll, L., Whitbeck, J.C., Ponce de Leon, M., Lou, H., Pannell, L.K.,
Lebowitz, J., Fogg, C., White, C.L., Moss, B., Cohen, G.H., Eisenberg, R.J.,
2005b. Physical and immunological characterization of a recombinant
secreted form of the membrane protein encoded by the vaccinia virus L1R
gene. Virology 341, 59–71.
Altman, J.D., Moss, P.A.H., Goulder, P.J.R., Barouch, D.H., McHeyzer-
Williams, M.G., Bell, J.I., McMichael, A.J., Davis, M.M., 1996. Phenotypic
analysis of antigen-specific T lymphocytes. Science 274, 94–96.
Amara, R.R., Villinger, F., Altman, J.D., Lydy, S.L., O'Neil, S.P., Staprans, S.I.,
Montefiori, D.C., Xu, Y., Herndon, J.G., Wyatt, L.S., Candido, M.A., Kozyr,
N.L., Earl, P.L., Smith, J.M., Ma, H.-L., Grimm, B.D., Hulsey, M.L.,
McClure, H.M., McNicholl, J.M., Moss, B., Robinson, H.L., 2001. Control
of a mucosal challenge and prevention of AIDS in rhesus macaques by a
multiprotein DNA/MVA vaccine. Science 292, 69–74.
Amara, R.R., Smith, J.M., Staprans, S.I., Montefiori, D.C., Villinger, F., Altman,
J.D., O'Neil, S.P., Kozyr, N.L., Xu, Y., Wyatt, L.S., Earl, P.L., Herndon,
J.G., McNicholl, J.M., McClure, H.M., Moss, B., Robinson, H.L., 2002a.
Critical role for Env as well as Gag-Pol in control of a simian-human
immunodeficiency virus 89.6P challenge by a DNA prime/recombinant
modified vaccinia virus Ankara vaccine. J. Virol. 76, 6138–6146.
Amara, R.R., Villinger, F., Staprans, S.I., Altman, J.D., Montefiori, D.C., Kozyr,
N.L., Xu, Y., Wyatt, L.S., Earl, P.L., Herndon, J.G., McClure, H.M., Moss,
B., Robinson, H.L., 2002b. Different patterns of immune responses but
similar control of a simian-human immunodeficiency virus 89.6P mucosal
challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA
vaccines. J. Virol. 76, 7625–7631.
Antoine, G., Scheiflinger, F., Dorner, F., Falkner, F.G., 1998. The complete
genomic sequence of the modified vaccinia Ankara strain: comparison with
other orthopoxviruses. Virology 244, 365–396.
Anton, L.C., Schubert, U., Bacik, I., Princiotta, M.F., Wearsch, P.A., Gibbs, J.,
Day, P.M., Realini, C., Rechsteiner, M.C., Bennink, J.R., Yewdell, J.W.,
1999. Intracellular localization of proteasomal degradation of a viral antigen.
J. Cell Biol. 146, 113–124.
Barouch, D.H., Craiu, A., Santra, S., Egan, M.A., Schmitz, J.E., Kuroda, M.J.,
Fu, T.M., Nam, J.H., Wyatt, L.S., Lifton, M.A., Krivulka, G.R., Nickerson,
C.E., Lord, C.I., Moss, B., Lewis, M.G., Hirsch, V.M., Shiver, J.W., Letvin,
N.L., 2001a. Elicitation of high-frequency cytotoxic T-lymphocyte
responses against both dominant and subdominant simian-human immuno-
deficiency virus epitopes by DNA vaccination of rhesus monkeys. J. Virol.
75, 2462–2467.
Barouch, D.H., Santra, S., Kuroda, M.J., Schmitz, J.E., Plishka, R., Buckler-
White, A., Gaitan, A.E., Zin, R., Nam, J.-H., Wyatt, L., Lifton, M.A.,
Nicherson, C.E., Moss, B., Montefiori, D.C., Hirsch, V.M., Letvin, N.L.,
2001b. Reduction of simian-human immunodeficiency virus 89.6P viremia
in rhesus monkeys by recombinant modified vaccinia virus Ankara
vaccination. J. Virol. 75, 5151–5158.
Barouch, D.H., Pau, M.G., Custers, J.H., Koudstaal, W., Kostense, S., Havenga,
M.J., Truitt, D.M., Sumida, S.M., Kishko, M.G., Arthur, J.C., Korioth-
Schmitz, B., Newberg, M.H., Gorgone, D.A., Lifton, M.A., Panicali, D.L.,Nabel, G.J., Letvin, N.L., Goudsmit, J., 2004. Immunogenicity of
recombinant adenovirus serotype 35 vaccine in the presence of pre-existing
anti-Ad5 immunity. J. Immunol. 172, 6290–6297.
Blanchard, T.J., Alcami, A., Andrea, P., Smith, G.L., 1998. Modified vaccinia
virus Ankara undergoes limited replication in human cells and lacks several
immunomodulatory proteins: implications for use as a human vaccine.
J. Gen. Virol. 79, 1159–1167.
Cafaro, A., Titti, F., Fracasso, C., Maggiorella, M.T., Baroncelli, S., Caputo, A.,
Goletti, D., Borsetti, A., Pace, M., Fanales-Belasio, E., Ridolfi, B., Negri,
D.R., Sernicola, L., Belli, R., Corrias, F., Macchia, I., Leone, P., Michelini,
Z., ten Haaft, P., Butto, S., Verani, P., Ensoli, B., 2001. Vaccination with
DNA containing tat coding sequences and unmethylated CpG motifs
protects cynomolgus monkeys upon infection with simian/human immuno-
deficiency virus (SHIV89.6P). Vaccine 19, 2862–2877.
Carroll, M., Moss, B., 1997. Host range and cytopathogenicity of the highly
attenuated MVA strain of vaccinia virus: propagation and generation of
recombinant viruses in nonhuman mammalian cell line. Virology 244,
365–369.
Cline, A.N., Bess, J.W., Piatak Jr., M., Lifson, J.D., 2005. Highly sensitive SIV
plasma viral load assay: practical considerations, realistic performance
expectations, and application to reverse engineering of vaccines for AIDS.
J. Med. Primatol. 34, 303–312.
Crawford, J.M., Earl, P.L., Moss, B., Reimann, K.A., Wyand, M.S., Manson, K.H.,
Bilska, M., Zhou, J.T., Pauza, C.D., Parren, P.W., Burton, D.R., Sodroski, J.G.,
Letvin, N.L., Montefiori, D.C., 1999. Characterization of primary isolate-like
variants of simian-human immunodeficiency virus. J. Virol. 73, 10199–10207.
Douek, D.C., Kwong, P.D., Nabel, G.J., 2006. The rational design of an AIDS
vaccine. Cell 124, 677–681.
Drexler, I., Heller, K., Wahren, B., Erfle, V., Sutter, G., 1998. Highly attenuated
modified vaccinia virus Ankara replicates in baby hamster kidney cells, a
potential host for virus propagation, but not in various human transformed
and primary cells. J. Gen. Virol. 79 (Pt 2), 347–352.
Earl, P.L., Hugin, A.W., Moss, B., 1990. Removal of cryptic poxvirus
transcription termination signals from the human immunodediciency virus
type 1 envelope gene enhances expression and immunogenicity of a
recombinant vaccinia virus. J. Virol. 64, 2448–2451.
Earl, P.L., Sugiura, W., Montefiori, D.C., Broder, C.C., Lee, S.A., Wild, C.,
Lifson, J., Moss, B., 2001. Immunogenicity and protective efficacy of
oligomeric human immunodeficiency virustType 1 gp140. J. Virol. 75,
645–653.
Earl, P.L., Wyatt, L.S., Montefiori, D.C., Bilska, M., Woodward, R., Markham,
P.D., Malley, J.D., Vogel, T.U., Allen, T.M., Watkins, D.I., Miller, N., Moss,
B., 2002. Comparison of vaccine strategies using recombinant env-gag-pol
MVA with or without an oligomeric Env protein boost in the SHIV rhesus
macaque model. Virology 294, 270–281.
Earl, P.L., Americo, J.L., Moss, B., 2003. Development and use of a vaccinia
virus neutralization assay based on flow cytometric detection of green
fluorescent protein. J. Virol. 77, 10684–10688.
Earl, P.L., Americo, J.L., Wyatt, L.S., Eller, L.A., Whitbeck, J.C., Cohen,
G.H., Eisenberg, R.J., Hartmann, C.J., Jackson, D.L., Kulesh, D.A.,
Martinez, M.J., Miller, D.M., Mucker, E.M., Shamblin, J.D., Zwiers, S.H.,
Huggins, J.W., Jahrling, P.B., Moss, B., 2004. Immunogenicity of a
highly attenuated MVA smallpox vaccine and protection against monkey-
pox. Nature 428, 182–185.
Edghill-Smith, Y., Bray, M., Whitehouse, C.A., Miller, D., Mucker, E.,
Manischewitz, J., King, L.R., Robert-Guroff, M., Hryniewicz, A., Venzon,
D., Meseda, C., Weir, J., Nalca, A., Livingston, V., Wells, J., Lewis, M.G.,
Huggins, J., Zwiers, S.H., Golding, H., Franchini, G., 2005. Smallpox
vaccine does not protect macaques with AIDS from a lethal monkeypox
virus challenge. J. Infect Dis. 191, 372–381.
Egan, M.A., Chong, S.Y., Rose, N.F., Megati, S., Lopez, K.J., Schadeck, E.B.,
Johnson, J.E., Masood, A., Piacente, P., Druilhet, R.E., Barras, P.W.,
Hasselschwert, D.L., Reilly, P., Mishkin, E.M., Montefiori, D.C., Lewis,
M.G., Clarke, D.K., Hendry, R.M., Marx, P.A., Eldridge, J.H., Udem, S.A.,
Israel, Z.R., Rose, J.K., 2004. Immunogenicity of attenuated vesicular
stomatitis virus vectors expressing HIV type 1 Env and SIV Gag proteins:
comparison of intranasal and intramuscular vaccination routes. AIDS Res.
Hum. Retroviruses 20, 989–1004.
96 P.L. Earl et al. / Virology 366 (2007) 84–97Enserink, M., 2002. Bioterrorism. In search of a kinder, gentler vaccine. Science
296, 1594.
Fenner, F., Henderson, D.A., Arita, I., Jezek, Z., Ladnyi, I.D., 1988. Smallpox
and its eradication. Geneva: World Health Organization.
Franchini, G., Gurunathan, S., Baglyos, L., Plotkin, S., Tartaglia, J., 2004.
Poxvirus-based vaccine candidates for HIV: two decades of experience
with special emphasis on canarypox vectors. Expert Rev. Vaccines 3,
S75–S88.
Fulginiti, V.A., Papier, A., Lane, J.M., Neff, J.M., Henderson, D.A., 2003.
Smallpox vaccination: a review: Part II. Adverse events. Clin. Infect. Dis.
37, 251–271.
Hel, Z., Johnson, J.M., Tryniszewska, E., Tsai, W.P., Harrod, R., Fullen, J.,
Tartaglia, J., Franchini, G., 2002. A novel chimeric Rev, Tat, and Nef
(Retanef) antigen as a component of an SIV/HIV vaccine. Vaccine 20,
3171–3186.
Henderson, D.A., 1999. The looming threat of bioterrorism. Science 283,
1282–1297.
Hu, S.-L., 2005. Non-human primate models for AIDS vaccine research. Curr.
Drug Targets-Infect. Dis. 5, 193–201.
Karlsson, G.B., Halloran, M., Li, J., Park, I.W., Gomila, R., Reimann, K.A.,
Axthelm, M.K., Iliff, S.A., Letvin, N.L., Sodroski, J., 1997. Characterization
of molecularly cloned simian-human immunodeficiency viruses causing
rapid CD4+ lymphocyte depletion in rhesus monkeys. J. Virol. 71,
4218–4225.
LeDuc, J.W., Damon, I., Relman, D.A., Huggins, J., Jahrling, P.B., 2002.
Smallpox research activities: U.S. interagency collaboration, 2001. Emerg.
Infect. Dis. 8, 743–745.
Letvin, N.L., 2005. Progress toward an HIV vaccine. Annu. Rev. Med. 56,
213–223.
Maloy, K.J., Erdmann, I., Basch, V.S., S., Kramps, T.A., Zinkernagel, R.M.,
Oehen, S., Kuendig, T.M., 2001. Intralymphatic immunization enhances
DNA vaccination. Proc. Natl. Acad. Sci. 98, 3203–3299.
Mascola, J.R., 2003. Defining the protective antibody response for HIV-1. Curr.
Mol. Med. 3, 209–216.
Mayr, A., Stickl, H., 1975a. Abstammung, eigenschaften und verwendung des
attenuieten vaccinia-stammes MVA. Infection 3, 6–14.
Mayr, A., Hochstein-Mintzel, V., Stickl, H., 1975b. Passage history, properties,
and applicability of the attenuated vaccinia virus strain MVA. Infection 3,
6–14.
Meyer, H., Sutter, G., Mayr, A., 1991. Mapping of deletions in the genome of
the highly attenuated vaccinia virus MVA and their influence on virulence.
J. Gen. Virol. 72 (Pt 5), 1031–1038.
Moss, B., 1996. Genetically engineered poxviruses for recombinant gene
expression, vaccination, and safety. Proc. Natl. Acad. Sci. U.S.A. 93,
11341–11348.
Nigam, P., Earl, P.L., Americo, J.L., Sharma, S., Wyatt, L.S., Edghill-Spano, Y.,
Chennareddi, L.S., Silvera, P., Moss, B., Robinson, H.L., Amara, R.R.,
2007. DNA/MVA HIV-1/AIDS vaccine elicits long-lived vaccinia virus-
specific immunity and confers protection against a lethal monkeypox
challenge. Virology 366, 73–83.
Norbury, C.C., Malide, D., Gibbs, J.S., Bennink, J.R., Yewdell, J.W., 2002.
Visualizing priming of virus-specific CD8+ T cells by infected dendritic cells
in vivo. Nat. Immunol. 3, 265–271.
Otten, G.R., Schaefer, M., Doe, B., Liu, H., Megede, J.Z., Donnelly, J.,
Rabussay, D., Barnett, S., Ulmer, J.B., 2006. Potent immunogenicity of an
HIV-1 gag-pol fusion DNA vaccine delivered by in vivo electroporation.
Vaccine 24, 4503–4509.
Ourmanov, I., Brown, C.R., Moss, B., Carroll, M., Wyatt, L., Pletneva, L.,
Goldstein, S., Venzon, D., Hirsch, V.M., 2000. Comparative efficacy of
recombinant modified vaccinia virus Ankara expressing simian immunode-
ficiency virus (SIV) gag-Pol and/or env in macaques challenged with
pathogenic SIV. J. Virol. 74, 2740–2751.
Peng, B., Wang, L.R., Gomez-Roman, V.R., Davis-Warren, A., Montefiori,
D.C., Kalyanaraman, V.S., Venzon, D., Zhao, J., Kan, E., Rowell, T.J.,
Murthy, K.K., Srivastava, I., Barnett, S.W., Robert-Guroff, M., 2005.
Replicating rather than nonreplicating adenovirus-human immunodefi-
ciency virus recombinant vaccines are better at eliciting potent cellular
immunity and priming high-titer antibodies. J. Virol. 79, 10200–10209.Rao, S.S., Gomez, P., Mascola, J.R., Dang, V., Krivulka, G.R., Yu, F., Lord, C.I.,
Shen, L., Bailer, R., Nabel, G.J., Letvin, N.L., 2006. Comparative evaluation
of three different intramuscular delivery methods for DNA immunization in
a nonhuman primate animal model. Vaccine 24, 367–373.
Reimann, K.A., Li, J.T., Veazey, R., Halloran, M., Park, I.W., Karlsson, G.B.,
Sodroski, J., Letvin, N.L., 1996. A chimeric simian/human immunodefi-
ciency virus expressing a primary patient human immunodeficiency virus
type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus
monkeys. J. Virol. 70, 6922–6928.
Richardson, M.W., Mirchandani, J., Silvera, P., Regulier, E.G., Capini, C.,
Bojczuk, P.M., Hu, J., Gracely, E.J., Boyer, J.D., Khalili, K., Zagury, J.F.,
Lewis, M.G., Rappaport, J., 2002. Immunogenicity of HIV-1 IIIB and SHIV
89.6P Tat and Tat toxoids in rhesus macaques: induction of humoral and
cellular immune responses. DNA Cell Biol. 21, 637–651.
Shiver, J.W., Fu, T.M., Chen, L., Casimiro, D.R., Davies, M.E., Evans, R.K.,
Zhang, Z.Q., Simon, A.J., Trigona, W.L., Dubey, S.A., Huang, L., Harris,
V.A., Long, R.S., Liang, X., Handt, L., Schleif, W.A., Zhu, L., Freed, D.C.,
Persaud, N.V., Guan, L., Punt, K.S., Tang, A., Chen, M., Wilson, K.A.,
Collins, K.B., Heidecker, G.J., Fernandez, V.R., Perry, H.C., Joyce, J.G.,
Grimm, K.M., Cook, J.C., Keller, P.M., Kresock, D.S., Mach, H., Troutman,
R.D., Isopi, L.A., Williams, D.M., Xu, Z., Bohannon, K.E., Volkin, D.B.,
Montefiori, D.C., Miura, A., Krivulka, G.R., Lifton, M.A., Kuroda, M.J.,
Schmitz, J.E., Letvin, N.L., Caulfield, M.J., Bett, A.J., Youil, R., Kaslow,
D.C., Emini, E.A., 2002. Replication-incompetent adenoviral vaccine vector
elicits effective anti-immunodeficiency-virus immunity. Nature 415,
331–335.
Sriwanthana, B., Hodge, T., Mastro, T.D., Dezzutti, C.S., Bond, K., Stephens,
H.A., Kostrikis, L.G., Limpakarnjanarat, K., Young, N.L., Qari, S.H., Lal,
R.B., Chandanayingyong, D., McNicholl, J.M., 2001. HIV-specific
cytotoxic T lymphocytes, HLA-A11, and chemokine-related factors may
act synergistically to determine HIV resistance in CCR5 delta32-negative
female sex workers in Chiang Rai, northern Thailand. AIDS Res. Hum.
Retroviruses 17, 719–734.
Stickl, H., Hochstein-Mintzel, V., Mayr, A., Huber, H.C., Schafer, H., Holzner,
A., 1974. [MVA vaccination against smallpox: clinical tests with an
attenuated live vaccinia virus strain (MVA) (author's transl)]. Dtsch. Med.
Wochenschr. 99, 2386–2392.
Stittelaar, K.J., Kuiken, T., de Swart, R.L., van Amerongen, G., Vos, H.W.,
Niesters, H.G.M., van Schalkwijk, P., van der Kwast, T., Wyatt, L.W., Moss,
B., Osterhaus, A.D.M.E., 2001. Safety of modified vaccinia virus Ankara
(MVA) in immune-suppressed macaques. Vaccine 19, 3700–3709.
Stittelaar, K.J., van Amerongen, G., Kondova, I., Kuiken, T., van Lavieren, R.F.,
Pistoor, F.H., Niesters, H.G., van Doornum, G., van der Zeijst, B.A., Mateo,
L., Chaplin, P.J., Osterhaus, A.D., 2005. Modified vaccinia virus Ankara
protects macaques against respiratory challenge with monkeypox virus.
J. Virol. 79, 7845–7851.
Sugiura, W., Broder, C.C., Moss, B., Earl, P.L., 1999. Characterization of
conformation-dependent anti-gp120 murine monoclonal antibodies pro-
duced by immunization with monomeric and oligomeric human immuno-
deficiency virus type 1 envelope proteins. Virology 254, 257–267.
Sutter, G., Moss, B., 1992. Nonreplicating vaccinia vector efficiently expresses
recombinant genes. Proc. Natl. Acad. Sci. U.S.A. 89, 10847–10851.
Sutter, G., Wyatt, L.S., Foley, P.L., Bennink, J.R., Moss, B., 1994. A
recombinant vector derived from the host-range-restricted and highly
attenuated MVA strain of vaccinia virus stimulates protective immunity in
mice to influenza virus. Vaccine 12, 1032–1040.
Van Rompay, K.K., Abel, K., Lawson, J.R., Singh, R.P., Schmidt, K.A.,
Evans, T., Earl, P., Harvey, D., Franchini, G., Tartaglia, J., Montefiori,
D., Hattangadi, S., Moss, B., Marthas, M.L., 2005. Attenuated poxvirus-
based simian immunodeficiency virus (SIV) vaccines given in infancy
partially protect infant and juvenile macaques against repeated oral
challenge with virulent SIV. J. Acquired Immune Defic. Syndr. 38,
124–134.
Wang, R., Epstein, J., Baraceros, F.M., Gorak, E.J., Charoenvit, Y., Carucci, D.J.,
Hedstrom, R.C., Rahardjo, N., Gay, T., Hobart, P., Stout, R., Jones, T.R.,
Richie, T.L., Parker, S.E., Doolan, D.L., Norman, J., Hoffman, S.L., 2001.
Induction of CD4(+) Tcell-dependent CD8(+) type 1 responses in humans by
a malaria DNA vaccine. Proc. Natl. Acad. Sci. U.S.A. 98, 1022–10817.
97P.L. Earl et al. / Virology 366 (2007) 84–97Wyatt, L.S., Earl, P.L., Eller, L.A., Moss, B., 2004. Highly attenuated smallpox
vaccine protects mice with and without immune deficiencies against pathogenic
vaccinia virus challenge. Proc. Natl. Acad. Sci. U.S.A. 101, 4590–4595.
Xu, R., Srivastava, I.K., Kuller, L., Zarkikh, I., Kraft, Z., Fagrouch, Z., Letvin,
N.L., Heeney, J.L., Barnett, S.W., Stamatatos, L., 2006. Immunization with
HIV-1 SF162-derived envelope gp140 proteins does not protect macaquesfrom heterologous simian-human immunodeficiency virus SHIV89.6P
infection. Virology 349, 276–289.
Zaucha, G.M., Jahrling, P.B., Geisbert, T.W., Swearengen, J.R., Hensley, L.,
2001. The pathology of experimental aerosolized monkeypox virus infection
in cynomolgus monkeys (Macaca fascicularis). Lab. Invest. 81,
1581–1600.
